

Woodham Lane, New Haw, Addlestone, Surrey KT15 3LS Telephone +44 (0)1932 336911

Post Authorisation Assessments

Eqvalan Duo, Oral Paste Vm 08327/5003

09 April 2025	Alignment of the product information with version 3 of the GB SPC/QRD template.
04 March 2025	Submission of an updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance.
16 November 2023	Update to a Ph. Eur. CEP for an already authorised manufacturer of the active substance.
25 August 2023	Widening the average dose limits of the ejectable content specification.
26 April 2023	Change in the name or address or contact details of a qualified person for pharmacovigilance.
24 August 2022	Submission of a new certificate of suitability from a new manufacturer.
16 August 2022	Change in address of manufacturer of the finished product.
22 October 2021	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.
21 September 2020	Minor change in the manufacturing process of the finished product.
28 May 2020	Change in the name of a manufacturer of the finished product, also responsible for batch release.
29 January 2020	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
05 November 2019	Change in the safety database of an existing pharmacovigilance system as described in the DDPS.
07 February 2019	Change in the name of the manufacturer of the finished product.
16 November 2018	Change in the name and address of the marketing authorisation holder from Merial Animal Health Limited, Sandringham House, Sandringham Avenue, Harlow Business Park, Harlow, Essex, CM19 5TG, United Kingdom to Boehringer Ingelheim Animal Health UK Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom.
20 June 2018	Change in RMS from UK to FR.
01 March 2018	Submission of an updated Ph. Eur. certificate of suitability for an active substance from an already approved manufacturer.
30 August 2017	Change in the address of the marketing authorisation holder in BE, DK, FI, LU, NO, PT, ES & SE only.

06 April 2017	Change to part of the packaging material not in contact
	with the finished product formulation.
08 December 2015	Change in the QPPV and/or QPPV contact details and/or back-up procedure
26 June 2015	Submission of an updated Ph. Eur. Certificate of Suitability.
08 May 2015	Submission of an updated Ph. Eur. Certificate of Suitability.
12 June 2014	Change of MAH address in Portugal only.
04 April 2014	Change of MAH address in Spain only.
16 January 2014	Change of the MAH address in Belgium.
18 January 2013	Addition of a supplier of packaging components or the finished product
13 September 2012	Minor changes to the manufacturing process of the finished product
03 August 2012	Deletion of a manufacturer of an active substance Submission of updated Ph. Eur. Certificates of Suitability for an active substance from already approved manufacturers
04 November 2011	Change of specification parameter for the finished product
26 July 2010	Addition of an indication against Anoplocephala magna
08 April 2010	Change of product name in Denmark only
29 January 2010	Renewal
21 January 2010	Addition of a 50 syringe pack size
29 December 2009	Submission of updated Ph. Eur. Certificates of Suitability for an active substance from an already approved manufacturer
20 November 2009	Replacement of a manufacturing site for all of the manufacturing process except batch release Minor change in manufacture of the finished product
04 November 2009	Change of batch size
03 February 2009	Deletion of a manufacturing site for packaging and control
07 August 2008	Change of specification of the finished product
03 January 2008	Addition of 2 manufacturers of the active substance
22 October 2007	Change of name of manufacturing site of the finished product
09 August 2006	Change of legal category from PML to POM-VPS
07 June 2006	Removal of safety warning regarding use in pregnant and lactating mares Decrease of minimum age of use of product in foals from 5 months to 2 months
25 May 2005	Mutual recognition procedure, UK as RMS Change of source of an excipient